Informations générales (source: ClinicalTrials.gov)
Quality of Life Assessment in Patients Undergoing Prolonged Suppressive Antibiotherapy for Prosthetic Joint Infection.
Interventional
N/A
Groupe Hospitalier Diaconesses Croix Saint-Simon (Voir sur ClinicalTrials)
novembre 2016
juin 2025
17 septembre 2025
Prosthetic joint infection (PJI) management is complex and requires prosthesis
replacement when symptoms duration is greater than 30 days or debridement with modular
set replacement when symptoms duration is lesser than one month. Nevertheless, the
prolonged suppressive antibiotherapy (PSA) is the single treatment we can provide to high
risk surgical patients and those who refuse reoperation.
There is limited data available on PSA modality, its tolerance and efficacy, this lack of
data motivated us to concept a prospective study of long term patient follow up with PJI
treated with prolonged suppressive antibiotherapy.
Etablissements
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| GRPE HOSP DIACONESSES-CROIX ST-SIMON | Simon MARMOR, MD | Contact (sur clinicalTrials) | |||
| HOPITAL DE LA CROIX SAINT SIMON | Younes KERROUMI, Doctorate | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Patient aged over 18 years old with hip or knee prosthetic infection who consented
to participate in the study
- Non-eligible patient to surgical treatment
- Patient eligible to prolonged suppressive antibiotherapy
- Patient aged over 18 years old with hip or knee prosthetic infection who consented
to participate in the study
- Non-eligible patient to surgical treatment
- Patient eligible to prolonged suppressive antibiotherapy
- patient who does not meet eligibility criteria
- Patient living or traveling abroad for whom 2 years minimum follow up is impossible.
- Patient lawfully deprived of his liberty
- Patient not insured under social security scheme